"今年1-4月，广州全市新设外商投资企业2662家，同比增长14.8%""实际使用外资115.2亿元人民币，同 比增长1.4%，增速高于全国""过去5年，全市实际使用外资总额近2800亿元，在穗投资500强企业增至 362家、落地项目2025个""全市5.02万家外资企业以1.8%的企业数占比，贡献了近三成进出口总值以及 近四成工业总产值和规上工业增加值。"……5月20日，在广州市重点外资企业圆桌会上公布的一组组数 据显示出，在全球经济复苏承压背景下，广州这座"千年商都"再次彰显出强劲的经济韧性与活力，吸引 着跨国企业持续加码。 据悉，本次是广州连续第5年举办外资企业圆桌会，会上宝洁、安利、广汽丰田、林德、玛氏箭牌、太 古地产、中国欧盟商会华南分会、新世界、捷普电子、瑞穗银行、现代汽车氢燃料公司、百吉生物等12 家外资企业和机构代表畅谈投资规划，提出发展诉求和政策建议，商务、发改、科技、工信、市场监管 等部门负责人现场回应，并建立台账、全程督办，确保事事有着落、件件有回音。 政策创新筑巢引凤：从"亿元奖励"到"精准滴灌" 以政策促改革，以创新促发展，一个吸引外资的政策创新高地正在广州崛起。 "我们一年内获得了 ...

泰国财政部长：希望与美国生物技术公司、食品加工企业及健康产业展开合作。 ...

Core Points - The Guangxi Activity Week at the China Pavilion during the 2025 Osaka Expo will take place from June 11 to 13, with the theme "Beautiful Guangxi, Green Future" [1][2] - The event will feature a series of activities categorized as "4+3+N," including an opening ceremony, exhibitions, intangible cultural heritage performances, and cultural shows, aimed at showcasing Guangxi's achievements and promoting economic and cultural exchanges globally [1][2] Group 1 - The "Encountering Unique Guangxi" section will host the "Green · Coexistence · Towards the Future" exhibition, utilizing a combination of physical and digital technologies to highlight Guangxi's natural resources, ecological environment, and cultural heritage [1][2] - Featured products will include Guangxi's traditional items such as Zhuang brocade, Ni Xing pottery, and Liu Bao tea, alongside immersive projects like digital avatars and VR experiences to attract international visitors [1][2] Group 2 - The "Understanding Opportunities in Guangxi" section will leverage the Expo platform to showcase Guangxi's specialty products and facilitate business negotiations between Chinese and Japanese enterprises, focusing on ecological, energy, and health industries [2] - The "Spreading the Beauty of Guangxi" section will employ diverse media strategies to present Guangxi's ecological charm and cultural depth, integrating modern technology with traditional heritage for an immersive experience [2]

Group 1: Core Insights - The article highlights a significant shift in the health consumption behavior of young people, moving from passive to active consumption, and from selective to essential spending on health [1][2] - The "Z generation" is expected to become the dominant force in health consumption, driven by their increasing focus on health and wellness [2][3] Group 2: Trends in Health Consumption - Young consumers are increasingly favoring intelligent, convenient, personalized, and fashionable health products, indicating a new trend in health consumption [2][3] - The integration of technology in health products, such as smart health monitoring devices, is making health management a necessity rather than a luxury [3][4] Group 3: Cultural and Service Innovations - The fusion of traditional medicine with modern dietary trends is creating a new wave of health products that resonate with young consumers, such as herbal coffee and traditional health drinks [3][4] - Innovations in health services, including the use of virtual and augmented reality in fitness, are enhancing the convenience and accessibility of health-related activities for young people [4]

我省推进将健康融入所有政策 海南日报海口5月13日讯(海南日报全媒体记者 王洪旭)5月13日，海南日报全媒体记者从"海南自贸 港政策解读"系列主题新闻发布会(第三十七场)上获悉，《海南省将健康融入所有政策实施方案》(以下 简称《方案》)已于2025年3月17日印发实施，是全国首个从省级层面推动将健康融入所有政策的文件。 我省将开展重大健康风险干预跨部门专项行动、主动健康协同行动和健康影响评估行动等3个专项 行动，推动"将健康融入所有政策"从理论变为现实。其中，对于健康影响评估行动，我省已从2019年开 始在三亚、琼海等市县开展了试点，评估公共政策、重大工程项目等可能对健康造成的影响。目前，全 省已有超过70%的市县建立了健康影响评估工作框架，累计完成评估成果30余项。开展重大健康风险干 预跨部门专项行动，针对已经发现的健康问题、危险因素等，通过部门间协作，进行有效干预，力求实 现"大卫生，大健康"。开展主动健康协同行动，出发点和落脚点是实现健康事业产业协同发展。健康产 业在海南拥有较大市场潜力和区位优势，我省将依托各部门的主动健康项目，在改善人群健康的同时， 推动相关健康产业转型升级。 "将健康融入所有政策" ...

近期有几个与银发经济相关的数据，引起了小编的关注： 事实上，当我们以产业发展的角度来切入老龄化时代，不难发现相关产业内涵的不断延展和新空间。 国家统计局于2021年公布的《养老产业统计分类（2020）》将养老产业范围确定为：养老照护服务、老年 医疗卫生服务、老年健康促进与社会参与、老年社会保障、养老教育培训和人力资源服务、养老金融服 务、养老科技和智慧养老服务、养老公共管理、其他养老服务、老年用品及相关产品制造、老年用品及相 关产品销售和租赁、养老设施建设等12个大类，并进一步细分成51个中类和79个小类。 没错，讨论、关注以及掘金银发经济的人，越来越多了。 除了老龄人口基数变大这一点，这一年龄段人口的财富积累也是其备受关注的重要原因。中国人民银行发 布的《2019年中国城镇居民家庭资产负债情况调查》显示，如果按户主年龄分类，2019年我国56-64岁和 65岁以上群体家庭总资产分别达到约355.4万元和288.0万元，相较于青年群体拥有更多的财富积累，也为 市场进一步发掘其消费潜力奠定了基石。 一是去哪儿发布的《史上最火五一出游报告》显示，"五一"期间，55岁至60岁用户的酒店预订增幅同比达 到了43%，在 ...

由单一"传统化工"升级为"3+2"现代主导产业体系 水往低处流，人往高处走。近日，有着"三峡门户"之称的湖北宜昌市披露的一组数据显示，截至2024年 底，该市人才总量已达到86.2万人，城区新集聚人才超8万人。 与人才数量持续增长相对应的是，2024年，宜昌经济总量首次突破6000亿元，达到6191亿元，四年连跨 两个千亿台阶，并由此成为"中部非省会第一城"。 近年来，在构建"双循环"新发展格局与长江经济带战略纵深推进的大背景下，作为长江中上游区域性中 心城市、湖北省域副中心城市的宜昌，深入实施"双碳引领、枢纽赋能、强产兴城"发展战略，加快建 设"长江大保护典范城市"，走出了一条"聚人气、强动能、提能级"的具有自身特色的高质量发展之路。 在不确定性因素增加、城市竞争日趋激烈的今天，宜昌的持续发展进位，到底是如何实现的？背后又蕴 藏着怎样的独有密码？ 产业是城市发展的基石。产业强，则城市兴。梳理宜昌近年来的发展历程，可以发现，产业动能的更新 换代和持续壮大，可谓是其成功"逆袭"最为关键的因素之一。 01 在过去很长时间里，依托长江水运交通、水资源及矿产资源优势，化工产业一直是宜昌的支柱和优势产 业，在整个工业化 ...

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].

Core Viewpoint - In 2024, Dongfang Chuangye (600278) reported a total operating revenue of 35.429 billion yuan, a year-on-year increase of 5.30%, while the net profit attributable to shareholders decreased by 20.53% to 216 million yuan [2][3]. Financial Performance - The total operating revenue for 2024 was 35.429 billion yuan, up 5.30% from 2023 [2][3]. - The net profit attributable to shareholders was 216 million yuan, down 20.53% from the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was 115 million yuan, a decrease of 23.14% year-on-year [2][3]. - The net cash flow from operating activities was -212 million yuan, compared to 312 million yuan in the same period last year [2][3]. - Basic earnings per share for 2024 were 0.25 yuan, with a weighted average return on equity of 2.91% [2][3]. Dividend Distribution - The company proposed a dividend distribution plan of 0.74 yuan per 10 shares (including tax) for all shareholders [2]. Non-Recurring Gains and Losses - The total non-recurring gains and losses amounted to 102 million yuan, with fair value changes and disposal gains from financial assets and liabilities contributing 99.49 million yuan [2]. Asset and Liability Changes - As of the end of 2024, accounts receivable increased by 40.59%, while cash and cash equivalents decreased by 6.98% [46][49]. - The company's total liabilities saw a significant increase, with accounts payable rising by 35.76% and short-term borrowings increasing by 64.83% [49]. Research and Development - The R&D expenditure for 2024 was 15.97 million yuan, a year-on-year increase of 98.31%, representing 0.05% of operating revenue [52]. Shareholder Structure - The top ten shareholders included new entrants Jinlongxing and Hu Xiaofeng, replacing previous shareholders [61].

从历史数据来看，东方创业的营收增长并不稳定。2023年公司营收同比下降18.88%，2022年也下降了 4.75%。尽管2024年有所回升，但整体增长乏力，反映出公司在市场竞争中的弱势地位。尤其是在全球 经济复苏动能减弱、贸易摩擦加剧的背景下，公司主营业务的增长面临诸多挑战。 净利润持续下滑，盈利能力堪忧 2024年，东方创业归属净利润为2.16亿元，同比下降20.53%；扣非净利润为1.15亿元，同比下降 23.14%。这是公司净利润连续第三年下滑，2023年和2022年分别下降了26.36%和2.95%。净利润的持续 下滑表明，公司在提升盈利能力方面并未取得实质性进展。 2025年4月26日，东方国际创业股份有限公司（以下简称"东方创业"）发布了2024年年报。报告显示， 公司全年实现营业收入354.29亿元，同比增长5.30%；归属净利润为2.16亿元，同比下降20.53%。尽管 营收有所增长，但净利润的持续下滑暴露出公司在复杂市场环境下的盈利能力不足。 营收增长背后的隐忧 东方创业2024年营业收入达到354.29亿元，同比增长5.30%，较2023年的336.47亿元有所回升。然而， 这一增长并未带 ...